Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FXS5626 in Healthy Chinese Participants
NCT07695779Phase 1Recruiting
- Sponsor
- Fosun Pharma
- Start
- Aug 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing FXS5626 with Placebo (2 arms). Primary endpoints: QTcF Interval Change and Adverse Events at 1 week. Started Aug 2026; status: recruiting.
02
Drugs
FXS5626
Beyond the preview
Go deeper on NCT07695779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07695779.